Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Company Deals Digital

Baidu Health Partners with Yibang to Enhance Operations for Brick-and-Mortar Pharmacies

Fineline Cube Mar 21, 2024

Baidu Health has entered into a strategic partnership with Shanghai Yibang Medicine Information Technology Co.,...

Company Deals

Edan Instruments Partners with Global Health Labs to Develop AI-Enhanced Handheld Ultrasound

Fineline Cube Mar 21, 2024

Shenzhen-based Edan Instruments Inc. has forged a strategic partnership with Global Health Labs Inc. to...

Company Drug

FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL

Fineline Cube Mar 21, 2024

The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...

Policy / Regulatory

China Unveils Action Plan to Boost Foreign Investment and Open Economy Further

Fineline Cube Mar 21, 2024

The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...

Company

Simcere Pharmaceutical Reports 4.5% Revenue Growth in 2023 Amid Shifts in Profitability

Fineline Cube Mar 21, 2024

Simcere Pharmaceutical Group (HKG: 2096), based in China, has released its 2023 financial performance report,...

Company Deals

Sinopharm and Fresenius Kabi Expand Partnership to Enhance Drug Distribution and Healthcare Services

Fineline Cube Mar 21, 2024

China’s state-owned Sinopharm Group Co., Ltd. (HKG: 1099) has announced a new partnership with Germany’s...

Company Deals

Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology

Fineline Cube Mar 21, 2024

Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader...

Company Drug

iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment

Fineline Cube Mar 21, 2024

Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...

Company Drug

BMS Reports Positive Phase III Results for Opdivo and Yervoy in Advanced HCC

Fineline Cube Mar 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) announced this week that its Phase III study evaluating...

Company Deals

China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA

Fineline Cube Mar 21, 2024

China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...

Digital R&D

CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment

Fineline Cube Mar 21, 2024

The Centre for Artificial Intelligence and Robotics (CAIR), part of the Chinese Academy of Sciences...

Company Deals

VIVA Biotech Secures Licensing Deal with Lonza for Advanced Bispecific Antibody Technology

Fineline Cube Mar 21, 2024

VIVA Biotech Holdings (HKG: 1873), a China-based Contract Research Organization (CRO), has entered into a...

Company Drug

Antengene’s ATG-022 Advances to Dose Expansion Phase in Phase II CLINCH Study for Solid Tumors

Fineline Cube Mar 21, 2024

Antengene Corporation Ltd (HKG: 6996), a leading biopharmaceutical company based in China, has announced that...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Clinical Study of SYS6023 in Advanced Solid Tumors

Fineline Cube Mar 21, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent China-based biopharmaceutical company, has received approval from...

Company

3SBio Reports 13.8% Revenue Growth in 2023, Driven by Strong Sales of Core Biologics

Fineline Cube Mar 21, 2024

3SBio Inc. (HKG: 1530), a leading China-based biopharmaceutical company, has reported its 2023 financial results,...

Company

Innovent Biologics Reports 36.2% Revenue Growth in 2023, Highlights Robust Product Sales

Fineline Cube Mar 21, 2024

Innovent Biologics Inc. (HKG: 1801), a China-based biotechnology firm, has released its 2023 financial report,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase Ib/II Study of HRS2398 in Advanced Solid Tumors

Fineline Cube Mar 20, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Deals

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

Fineline Cube Mar 20, 2024

Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement...

Company Drug

CSPC Pharmaceutical Gets NMPA Greenlight for SYH2039 Clinical Study in Advanced Malignant Tumors

Fineline Cube Mar 20, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has received...

Company

Novo Nordisk Invests RMB 4 Billion to Expand Sterile Manufacturing in Tianjin

Fineline Cube Mar 20, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based leader in diabetes care, has announced a substantial investment...

Posts pagination

1 … 331 332 333 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.